These non-GAAP financial measures are computed by excluding certain items related to acquisitions, restructuring and certain other items from the related GAAP financial measures. Our stock price is volatile and may be affected by a number of events. Medicare Billing Guide. The Company generated $2.0 billion of free cash flow in the fourth quarter of 2020 versus $2.3 billion in the fourth quarter of 2019. Copy and paste multiple symbols separated by spaces. Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including the majority of amortization of intangible assets, whereas the tax impact of other adjustments, including restructuring initiatives, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. The Company generated $9.9 billion of free cash flow for the full year 2020 versus $8.5 billion in 2019.; The Company's fourth quarter 2020 dividend of $1.60 per share was declared on October 21, 2020, and was paid on … To request a copy, please fill out and sign the attached screening licensing agreement and the DVD request form and email to immunization@flhealth.gov. A triplet cohort combining sotorasib, a MEK inhibitor and an epidermal growth factor receptor (EGFR) antibody has also been initiated. Fourth Quarter Product and Pipeline Update. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. Don't be afraid to change your course temporarily. These symbols will be available throughout the site during your session. The FDA has approved Nplate for the treatment of Hematopoietic Syndrome of Acute Radiation Syndrome. For Blue Cross’ PPO members: Fax the medication request form to 1-866-601-4425. This policy update does not apply to our strategic investment in BeiGene, which is included in our non-GAAP results, and is accounted for under the equity method of accounting. The Milken Institute’s COVID-19 Treatment and Vaccine Tracker tracks the development of treatments and vaccines for COVID-19 (coronavirus). The adjustments related to certain acquisition items and prior period items excluded from GAAP earnings. SOLIRIS can lower the ability of your immune system to fight infections. N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Product Sales Detail by Product and Geographic Region, ** Other includes GENSENTA, IMLYGIC®, Corlanor®, Bergamo and AVSOLA®, Operating Expense, Operating Margin and Tax Rate Analysis, Note: Numbers may not add due to rounding. ", $Millions, except EPS, dividends paid per share and percentages. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. ERA Enrollment Form. Our team is fully remote and has worked hard to maintain connection and dedication to extraordinary work. A Phase 3 study evaluating the efficacy and safety of ABP 959 compared with Soliris (eculizumab) in adults with paroxysmal nocturnal hemoglobinuria has completed enrollment. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-reports-fourth-quarter-and-full-year-2020-financial-results-301220622.html. Medicare Billing Guide. The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates. ... SOLIRIS is a medicine that affects your immune system. The Company provided the following updates on selected product and pipeline programs: * Funding and execution of the pivotal study was provided by the National Institute of Allergy and Infectious Diseases (NIAID) and the Priority Review regulatory submission was conducted in partnership with the Biomedical Advanced Research and Development Authority (BARDA). ¨ Previously vaccinated Date: Meningococcal vaccines, administer as directed: Select one quadrivalent A, C, Y, W serotype vaccine (Men-C-ACYW): For more information, contact [email protected], or by calling 1-888-765-4747. Main Office Contact Portal Registration. “One SOURCE for ALL your Medical NEEDS” SOLIRIS ENROLLMENT FORM . THOUSAND OAKS, Calif., Feb. 2, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2020 versus comparable periods in 2019. Under the Soliris REMS, prescribers must enroll in the program. The path to success is always zig-zagging, and you never know which turn could be meaningful. Under the Soliris REMS, prescribers must enroll in the program. In November, Novartis announced positive results from a head-to-head trial where Aimovig demonstrated superiority vs. topiramate in achieving at least a 50% reduction from baseline in monthly migraine days. Commonly Used Forms for Providers ... We've included the common forms and resources you need most in one place for your convenience. Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation, changes in the fair value of our contingent consideration and changes in fair value of our equity investments. For the three and twelve months ended December 31, 2020, the adjustments related to the amortization of the basis difference from our BeiGene equity method investment. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. Cash Flow and Balance Sheet. Key results include: "In a year marked by the disruption of COVID-19, we served patients around the world without interruption, advanced our pipeline and delivered strong financial performance, all while keeping our employees safe," said Robert A. Bradway, chairman and chief executive officer. Do Not Sell My Personal Information (CA Residents Only). The Company uses certain non-GAAP financial measures to enhance an investor's overall understanding of the financial performance and prospects for the future of the Company's ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. Our business may be impacted by government investigations, litigation and product liability claims. 1 INDICATIONS AND USAGE 1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Enrollment in the Soliris REMS program and additional information are available by telephone: 1-888-SOLIRIS (1-888-765-4747) or at www.solirisrems.com. You simply have to keep going so that you can arrive somewhere. The only guarantee is change. */, For investors looking to understand what the stimulus bill means for stocks and the economy, Lit Markets Provide Price Improvement Too, Why Evoqua (AQUA) Doesn’t Fit the Present Profile of Other Growth Stocks, 3 Lessons for Investors From 1 Year of the Pandemic, Turning Over a New Leaf to Talk About This Cannabis Stock, 2 Top Stocks Investors Should Buy Right Now, Weekly Preview: Earnings to Watch This Week (COUP, CRWD, FDX, NKE), DocuSign (DOCU) 4th Quarter Earnings: What to Expect, AMC Entertainment (AMC) 4th Quarter Earnings: What to Expect, Oracle (ORCL) 3rd Quarter Earnings: What to Expect, Lincoln, Darwin, and Why You Should Be Optimistic About America, The Second Coup, And What Needs To Be Done Now, The Pardon of Richard Nixon and the End of American Accountability, The Downside of Deadlock: Why Paralyzed Government is Bad For Business and Ameri…, Nasdaq Files SEC Proposal to Advance Boardroom Diversity, How Companies Can Tap Into Diversity and Add Value, Nasdaq Private Market on Pace for Record Fourth Quarter, Anticipates Strong Pipeline for 2021. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. #block-survival { display: none; } @media only screen and (min-width: 75rem) { .multiple-lines-intraday-chart .content-3-up__item.content-3-up__item { flex-basis: 31%; }} An injectable and long-acting oral product are under production to begin clinical trials for COVID-19 and acute lung injury. 1 INDICATIONS AND USAGE This updated non-GAAP policy will become the basis for our comparisons going forward in 2021 and is reflected in our 2021 guidance. Access to Medicines Initiatives Outside the U.S. Amgen's Commitment to Diversity, Inclusion and Belonging, http://www.prnewswire.com/news-releases/amgen-reports-fourth-quarter-and-full-year-2020-financial-results-301220622.html, Q4 2020 Amgen Earnings Conference Call Presentation, For the fourth quarter, total revenues increased 7% to, Product sales increased 8% globally, driven by 13% volume growth across the portfolio, including Otezla, For the full year, total revenues increased 9% to, GAAP earnings per share (EPS) decreased 3% to, For the fourth quarter, GAAP operating income decreased 2% to, Non-GAAP EPS increased 5% in the fourth quarter to, For the fourth quarter, non-GAAP operating income increased 4% to, The Company's fourth quarter 2020 dividend of, During the fourth quarter of 2020, the Company repurchased 5.3 million shares of common stock at a total cost of, Regulatory submissions have been completed in the, Sotorasib has received Breakthrough Therapy Designation in the, The positive results of the registrational Phase 2 monotherapy study in patients with. Ten Phase 1b combination cohorts with sotorasib are enrolling patients with some initial data expected in H1 2021. [CDATA[>*/ Full-year product sales outside the U.S. grew 10%, with revenues in the Asia-Pacific region exceeding $1 billion for the first time. Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Primary … If only 1 dose of vaccine was administered before the 16th birthday, a booster dose should be administered before enrollment. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Type a symbol or company name. Soliris® (eculizumab) treats anti-AChR antibody-positive gMG. One of them, Kelly Pozzoli, allowed the filmmakers to follow her journey for more than 2 years from the time she was diagnosed until her death in 2014 on World Cancer Day. [CDATA[/* >